Early PD-1 Therapy Discontinuation in Responding Metastatic Cancer Patients.
CONCLUSION: The results of the current study suggest that patients whose PD-1 therapy has been discontinued in response can have a long IO therapy-free period without need for a next line of therapy.
PMID: 30380551 [PubMed - as supplied by publisher]
Source: Oncology - Category: Cancer & Oncology Authors: Iivanainen S, Koivunen JP Tags: Oncology Source Type: research
More News: Bladder Cancer | Cancer | Cancer & Oncology | Clinical Trials | Melanoma | Skin Cancer | Study